ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
The Value of Cardiac Magnetic Resonance Delayed Enhancement Combined with Tissue Tracking in Discriminating Cardiac Amyloidosis from Hypertrophic Cardiomyopathy
Provisionally accepted
- Ningbo Medical Centre Lihuili Hospital, Ningbo, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: Cardiac amyloidosis (CA) and hypertrophic cardiomyopathy (HCM) may both present with left ventricular hypertrophy, making differential diagnosis challenging. This study aimed to evaluate the value of cardiac magnetic resonance (CMR) delayed enhancement combined with tissue tracking (CMR-TT) in discriminating CA from HCM. Methods: Data from 30 patients with CA, 29 patients with HCM, and 20 normal controls (NC) were retrospectively analyzed. All subjects underwent CMR examinations. Tissue tracking techniques were adopted for CMR cine sequences to directly quantify global radial strain (GRS), global circumferential strain (GCS), and global longitudinal strain (GLS). Results: The most common delayed enhancement pattern in CA was linear subendocardial enhancement (76.7%). Half of the CA patients had delayed enhancement involving atria and right ventricle, while 33.3% exhibited the characteristic “chaotic sign.” The GRS and GCS values were significantly different between the CA group and the HCM group and between the CA group and the NC group (P<0.05). GLS differed significantly among the CA, HCM, and NC groups (P<0.05). ROC analysis revealed that GCS (AUC=0.748, P=0.001) and GLS (AUC=0.732, P=0.002) provided good diagnostic efficiency in differentiating CA from HCM. Conclusion: CMR delayed enhancement patterns combined with myocardial strain parameters, particularly GLS and GCS, can aid in the differential diagnosis of CA and HCM. Optimal cutoff values of GCS (–14.6%) and GLS (–9.22%) provide a noninvasive imaging approach with significant clinical implications for guiding treatment and improving prognosis.
Keywords: Amyloidosis, Hypertrophic Cardiomyopathy, Magnetic Resonance Imaging, Ventricular Function, Medicine
Received: 25 Sep 2025; Accepted: 25 Nov 2025.
Copyright: © 2025 Xue, Xu, Lin, Wang and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiao-Gang Xue
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.